Rezolute is conducting two Phase 3 trials for its first-in-class monoclonal antibody therapy, ersodetug, aimed at treating hypoglycemia due to hyperinsulinism. The study highlights challenges in demonstrating therapeutic benefit in ultra-rare diseases, emphasizing the need for alternative approaches beyond traditional RCTs.